Trial Profile
Efficacy of Olaratumab and Rechallenge With Doxorubicin in Anthracycline Pretreated, Advanced Soft Tissue Sarcoma Patients. An Exploratory Phase-II Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary) ; Dexrazoxane; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms OlaReDo
- 05 Jul 2020 Status changed from suspended to discontinued.
- 30 Jan 2019 Status changed from recruiting to suspended.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.